Please use this identifier to cite or link to this item:
DC FieldValue
dc.titleLong-term results of liver transplant in patients with chronic viral hepatitis-related liver disease in Singapore
dc.contributor.authorWai, C.T.
dc.contributor.authorDa Costa, M.
dc.contributor.authorSutedja, D.
dc.contributor.authorLee, Y.M.
dc.contributor.authorLee, K.H.
dc.contributor.authorTan, K.C.
dc.contributor.authorIsaac, J.
dc.contributor.authorWee, A.
dc.contributor.authorPrabhakaran, K.
dc.contributor.authorLim, S.-G.
dc.identifier.citationWai, C.T., Da Costa, M., Sutedja, D., Lee, Y.M., Lee, K.H., Tan, K.C., Isaac, J., Wee, A., Prabhakaran, K., Lim, S.-G. (2006-07). Long-term results of liver transplant in patients with chronic viral hepatitis-related liver disease in Singapore. Singapore Medical Journal 47 (7) : 588-591. ScholarBank@NUS Repository.
dc.description.abstractIntroduction: Liver disease from chronic hepatitis B (CHB) and C (CHC) constitutes 57 percent of adult liver transplant in Singapore. Their long-term results post-transplant may be affected by recurrence of the viral illness. This study aims to evaluate the long-term results and survival in patients transplanted for CHB- and CHC-related liver disease. Methods: Patients transplanted for CHB- and CHC-related disease from 1990 until March 2004, which included decompensated cirrhosis and hepatocellular carcinoma (HCC), were reviewed and analysed. Results: 25 patients were transplanted for CHB-related liver disease, with mean follow-up of 153 ± 25 weeks. Two- and four-year survival rates were 75 percent and 69 percent, respectively. Hepatitis B recurrence from YMDD mutants occurred in five patients, and four were treated successfully with adefovir dipivoxil, with resolution in transaminases and/or improvement in histology. One patient became non-compliant with follow-up and medications, and died 173 weeks post-transplant from reactivation of the wild-type hepatitis B virus. Nine patients were transplanted for CHC-related liver disease, with mean follow-up of 188 ± 40 weeks, and two- and four-year survival rates of 89 percent and 76 percent, respectively. Two patients developed hepatitis C recurrence and were treated with interferon and ribavarin. One responded with sustained response but the other remained viraemic and died of HCC recurrence two years post-transplant. Conclusion: Long-term results from CHB- and CHC-related liver diseases were satisfactory and comparable to major transplant centres in the USA and Europe. Recurrence of viral hepatitis post-transplant is controllable with current antiviral therapy.
dc.subjectAnti-viral agents
dc.subjectChronic hepatitis B
dc.subjectChronic hepatitis C
dc.subjectLiver transplantation
dc.description.sourcetitleSingapore Medical Journal
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Page view(s)

checked on Jan 26, 2023

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.